Tomatidine and Microbiome Modulation for Osteoporosis Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for osteoporosis are inadequate, leading to significant bone loss and fragility fractures, with existing medications causing adverse events such as mandibular osteonecrosis and increased tumor risk, necessitating the development of novel therapeutic targets to prevent and treat the disease effectively.
Innovation Solution
A method involving the modification of an individual's gut microbiome using a pharmaceutical formulation containing tomatidine, rapamycin, and xylitol, along with probiotic bacteria like Lactobacillus reuteri and Faecalibacterium prausnitzii, to enhance bone strength and reduce osteoporosis risk, while also addressing inflammatory conditions and muscle atrophy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing medications are used to treat osteoporosis, then bone loss is addressed, but adverse events such as mandibular osteonecrosis and increased tumor risk occur
Solution Approach 1:
The patent extracts and eliminates harmful side effects by using a natural compound (tomatidine from green tomatoes) that specifically targets osteoclasts to inhibit bone resorption, thereby removing the adverse events associated with conventional medications while maintaining therapeutic effectiveness
Solution Approach 2:
The patent employs a natural, readily available compound (tomatidine from green tomatoes) as a temporary but effective treatment alternative that achieves bone protection without the long-term harmful accumulation and severe side effects of synthetic medications
2Reliability
If conventional osteoporosis treatments are administered, then bone density is maintained, but the complexity of treatment protocols and monitoring increases
Solution Approach 1:
The patent makes tomatidine a multi-functional agent that not only inhibits osteoclast activity to maintain bone density but also reduces inflammation and prevents tumor growth, thereby consolidating multiple therapeutic functions into a single treatment protocol
Solution Approach 2:
The patent leverages the body's natural processes by using tomatidine to stimulate osteoblast activity and promote bone formation through physiological pathways, reducing the need for complex external monitoring and intervention protocols
Data Source
AI summary
Various embodiments of the present invention are directed to the field of treating and preventing osteoporosis, with particular embodiments directed to a method of ameliorating, treating, or preventing osteoporosis in a human subject employing tomatidine, xylitol, rapamycin, etc., as well as modifying an individual's microbiome to reduce the likelihood of osteoporosis.